DataMeds AI, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $MEDS in the last 30 days.
See all $MEDS insider activity →DataMeds AI (MEDS) settled litigation, repurchased 364,099 shares for $350,000, and issued 666,667 shares in a tech license deal. The company's stockholders' equity now exceeds $2.5M, with $19M in liabilities extinguished.
DataMeds AI, Inc. (MEDS) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As of October 13, 2026, DataMEDS AI, Inc. (the “Company”) confirms that its stockholders’ equity is greater than $2,500,000. The transactions below resulted in the increase to the Company’s stockholders’ equity. On September 11, 2026, the Company entered i
DataMEDS AI (NASDAQ:MEDS) implemented cost-cutting measures, focusing on ChemoFx commercialization. ChemoFx, a diagnostic lab test for chemotherapy regimen selection, was included in a Humana Medicaid coverage policy. The company aims to relaunch marketing efforts and publish additional clinical utility data. DataMEDS also plans to collaborate on research using its tumor sample repository.
Over the past 7 days, AlphAI's AI scored 18 news stories mentioning MEDS (DataMeds AI, Inc.). Coverage has skewed bullish: 14 bullish, 3 neutral, and 1 bearish.
Recent MEDS coverage spans financial news, market movers and corporate actions.
Settlement and equity confirmation should reduce balance-sheet risk, while the share issuance adds dilution offset by extinguished liabilities.
Settlement reduces reported liabilities and supports equity adequacy, but the share issuance to REBOOT adds dilution risk.
Focus on ChemoFx commercialization and payer coverage is a near-term execution catalyst, but the update lacks quantified financial targets.
The coverage decision may lift a key commercial barrier, supporting revenue growth from the Helomics subsidiary.
Near-term momentum likely remains supported by the AI platform narrative, Corexa revenue acceleration, and the Helomics oncology expansion, but liquidity risk can amplify downside on any execution hiccup.
AlphAI scores every news story that mentions MEDS with an AI model for sentiment and relevance, and aggregates insider trades from DataMeds AI, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
DataMeds AI (MEDS) settled litigation, repurchased 364,099 shares for $350,000, and issued 666,667 shares in a tech license deal. The company's stockholders' equity now exceeds $2.5M, with $19M in liabilities extinguished.
1 min readDataMeds AI, Inc. (MEDS) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As of October 13, 2026, DataMEDS AI, Inc. (the “Company”) confirms that its stockholders’ equity is greater than $2,500,000. The transactions below resulted in the increase to the Company’s stockholders’ equity. On September 11, 2026, the Company entered i
3 min readDataMEDS AI (NASDAQ:MEDS) implemented cost-cutting measures, focusing on ChemoFx commercialization. ChemoFx, a diagnostic lab test for chemotherapy regimen selection, was included in a Humana Medicaid coverage policy. The company aims to relaunch marketing efforts and publish additional clinical utility data. DataMEDS also plans to collaborate on research using its tumor sample repository.
4 min readDataMeds AI (NASDAQ:MEDS) subsidiary Helomics received Medicaid coverage for ChemoFx Assay in gynecologic cancers under Humana's policy, effective July 22, 2026. The assay measures tumor responses to chemotherapy, potentially increasing demand. Coverage is subject to clinical criteria and plan eligibility. Previous research suggests cost savings, but actual revenue impact remains uncertain.
2 min readDataMeds AI Inc. (MEDS) stock rose 18.92% after launching an AI platform for healthcare diagnostics. The company reported $23.3M in trailing revenue, but profitability metrics remain negative. Corexa Pharmacy division saw $1M in September revenue, up 66% from July. MEDS acquired Helomics, adding AI-driven cancer diagnostics, for $1.5M in stock and notes, and settled Wellgistics litigation, reducing liabilities by $19M. The stock is highly volatile, driven by catalysts and sentiment.
4 min readDataMeds AI (NASDAQ:MEDS) reported that Corexa Pharmacy, a division of its subsidiary Corexa Health, achieved over $1 million in September 2026 revenue, a 66% increase from July 2026. The growth is attributed to an expanded retail customer base and the launch of Tollo Health's products. The company expects continued growth due to recent acquisitions and strategic initiatives.
2 min readDataMeds AI reported Corexa Pharmacy's September revenue exceeded $1M, a 66% increase from July 2026, driven by retail growth and new product launches. The company attributes this to recent rebranding and new offerings.
1 min readDataMeds AI (NASDAQ:MEDS) shares rose 31.83% to $4.10 Monday after launching its 'Health Lives Here' app with Tollo Health and NFL Alumni Association. The app offers telemedicine, pharmacy services, and AI health coaching, with plans to expand to Long COVID and oncology patients by 2026. The company aims to add digital twin and blockchain features by 2027.
2 min readDataMeds AI stock rose 25% after launching the Health Lives Here app, targeting GLP-1 medication users. The app integrates telemedicine, prescriptions, and health tracking. The company plans to expand to Long COVID and cancer patients, and is building a national pharmacy network. DataMeds AI aims to create a comprehensive healthcare platform.
2 min readDataMeds AI Inc (NASDAQ:MEDS) shares rose 7.5% premarket after launching a new website post-acquisition. The company acquired Helomics' AI Cancer Diagnostics Lab, settled litigation, and plans to launch the Health Lives Here app. The website reflects AI-focused marketing efforts, according to the company.
1 min read
